Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study

• Published in: Expert review of pharmacoeconomics & outcomes research
• Main Authors: Nogueira, Vinícius Gonçalves, Reis, Edna Afonso, Godman, Brian, Martin, Antony Paul, Godói, Isabella Piassi Dias
• Format: Journal Article
• Language: English
• Published: England 24.07.2024
• Subjects: Brazil; contingent valuation; vaccine; HIV; Willingness to pay; Acceptability
• ISSN: 1744-8379
• DOI: 10.1080/14737167.2024.2384543

The Human Immunodeficiency Virus (HIV) is one of the greatest public health challenges still facing communities worldwide, and until this moment, no vaccine is available for its prevention. In Brazil, the Rio de Janeiro State has stood out regarding the prevalence of this disease. As a result, an important state to consider the Willingness to Pay (WTP) for a hypothetical HIV vaccine to help with future pricing. A cross-sectional study was conducted to assess the acceptability and WTP of individuals from Rio de Janeiro State for a hypothetical HIV vaccine with a 70% efficacy. 600 individuals were interviewed and the acceptability for this hypothetical vaccine was 77.2%. In addition, 452 participants were eligible for the WTP analysis and would accept a WTP US$79.37 (400 BRL) for this vaccine, a higher value than that found in another study (200 BRL) conducted in the Northern region of Brazil under the same methodological conditions. Economic studies such as WTP can contribute to discussions regarding the prices and specifications for future vaccines, particularly for a HIV vaccine in countries such as Brazil with over 5,000 municipalities spread across regions with diverse characteristics and challenges in terms of socioeconomic, epidemiological and cultural differences.